BACKGROUND: Genetic factors contribute to the development of anxiety disorders, yet few risk genes have been previously identified. One genomic approach that has achieved success in identifying risk genes in related childhood neuropsychiatric conditions is investigations of de novo variants, which has yet to be leveraged in childhood anxiety disorders. METHODS: We performed whole-exome DNA sequencing in 76 parent-child trios (68 trios after quality control) recruited from a childhood anxiety disorder clinic and compared rates of rare and ultra-rare de novo variants with 790 previously sequenced control trios (783 trios after quality control). We then explored overlap with risk genes for other neuropsychiatric conditions and enrichment in biologic pathways. RESULTS: Rare and ultra-rare de novo likely gene disrupting and predicted damaging missense genetic variants are enriched in anxiety disorder probands compared with controls (rare variant rate ratio 1.97, 95% confidence interval [CI]: 1.11-3.34, p = .03; ultra-rare variant rate ratio 2.59, 95% CI: 1.35-4.70, p = .008). These de novo damaging variants occur in individuals with a variety of childhood anxiety disorders and impact genes that have been associated with other neuropsychiatric conditions. Exploratory network analyses reveal enrichment of deleterious variants in canonical biological pathways. CONCLUSIONS: These findings provide a path for identifying risk genes and promising biologic pathways in childhood anxiety disorders by de novo genetic variant detection. Our results suggest the discovery potential of applying this approach in larger anxiety disorder cohorts to advance our understanding of the underlying biology of these common and debilitating conditions.
BACKGROUND: Genetic factors contribute to the development of anxiety disorders, yet few risk genes have been previously identified. One genomic approach that has achieved success in identifying risk genes in related childhood neuropsychiatric conditions is investigations of de novo variants, which has yet to be leveraged in childhood anxiety disorders. METHODS: We performed whole-exome DNA sequencing in 76 parent-child trios (68 trios after quality control) recruited from a childhood anxiety disorder clinic and compared rates of rare and ultra-rare de novo variants with 790 previously sequenced control trios (783 trios after quality control). We then explored overlap with risk genes for other neuropsychiatric conditions and enrichment in biologic pathways. RESULTS: Rare and ultra-rare de novo likely gene disrupting and predicted damaging missense genetic variants are enriched in anxiety disorder probands compared with controls (rare variant rate ratio 1.97, 95% confidence interval [CI]: 1.11-3.34, p = .03; ultra-rare variant rate ratio 2.59, 95% CI: 1.35-4.70, p = .008). These de novo damaging variants occur in individuals with a variety of childhood anxiety disorders and impact genes that have been associated with other neuropsychiatric conditions. Exploratory network analyses reveal enrichment of deleterious variants in canonical biological pathways. CONCLUSIONS: These findings provide a path for identifying risk genes and promising biologic pathways in childhood anxiety disorders by de novo genetic variant detection. Our results suggest the discovery potential of applying this approach in larger anxiety disorder cohorts to advance our understanding of the underlying biology of these common and debilitating conditions.
Authors: Gunnar Houge; Dorien Haesen; Lisenka E L M Vissers; Sarju Mehta; Michael J Parker; Michael Wright; Julie Vogt; Shane McKee; John L Tolmie; Nuno Cordeiro; Tjitske Kleefstra; Marjolein H Willemsen; Margot R F Reijnders; Siren Berland; Eli Hayman; Eli Lahat; Eva H Brilstra; Koen L I van Gassen; Evelien Zonneveld-Huijssoon; Charlotte I de Bie; Alexander Hoischen; Evan E Eichler; Rita Holdhus; Vidar M Steen; Stein Ove Døskeland; Matthew E Hurles; David R FitzPatrick; Veerle Janssens Journal: J Clin Invest Date: 2015-07-13 Impact factor: 14.808
Authors: Kristian Tambs; Nikolai Czajkowsky; Espen Røysamb; Michael C Neale; Ted Reichborn-Kjennerud; Steven H Aggen; Jennifer R Harris; Ragnhild E Ørstavik; Kenneth S Kendler Journal: Br J Psychiatry Date: 2009-10 Impact factor: 9.319
Authors: Daniel F Levey; Joel Gelernter; Renato Polimanti; Hang Zhou; Zhongshan Cheng; Mihaela Aslan; Rachel Quaden; John Concato; Krishnan Radhakrishnan; Julien Bryois; Patrick F Sullivan; Murray B Stein Journal: Am J Psychiatry Date: 2020-01-07 Impact factor: 18.112
Authors: Gerald Nestadt; David B Goldstein; Mathew Halvorsen; Jack Samuels; Ying Wang; Benjamin D Greenberg; Abby J Fyer; James T McCracken; Daniel A Geller; James A Knowles; Anthony W Zoghbi; Tess D Pottinger; Marco A Grados; Mark A Riddle; O Joseph Bienvenu; Paul S Nestadt; Janice Krasnow; Fernando S Goes; Brion Maher Journal: Nat Neurosci Date: 2021-06-28 Impact factor: 24.884
Authors: Sheng Wang; Jeffrey D Mandell; Yogesh Kumar; Nawei Sun; Montana T Morris; Juan Arbelaez; Cara Nasello; Shan Dong; Clif Duhn; Xin Zhao; Zhiyu Yang; Shanmukha S Padmanabhuni; Dongmei Yu; Robert A King; Andrea Dietrich; Najah Khalifa; Niklas Dahl; Alden Y Huang; Benjamin M Neale; Giovanni Coppola; Carol A Mathews; Jeremiah M Scharf; Thomas V Fernandez; Joseph D Buxbaum; Silvia De Rubeis; Dorothy E Grice; Jinchuan Xing; Gary A Heiman; Jay A Tischfield; Peristera Paschou; A Jeremy Willsey; Matthew W State Journal: Cell Rep Date: 2018-09-25 Impact factor: 9.995